Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on November 14, 2022. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2022. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1), which is not included in the input content.
Material Changes
No specific material changes versus prior periods are detailed in this document. The filing solely indicates that results for the periods ended September 30, 2022, have been issued.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It explicitly states that the information furnished is not "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the correct registrant name is ReShape Lifesciences Inc. (RSLS), not Vyome Holdings, Inc.
- Locate and review Exhibit 99.1 (Press Release dated November 14, 2022) for actual financial figures.
- Confirm the reporting periods covered are the three and nine months ended September 30, 2022.
- Note that this 8-K is a notification of results rather than a detailed financial statement itself.